Possible Semaglutide Side Effects
Semaglutide has a well-documented favorable safety profile with a relatively low risk of side effects. Serious side effects have only been seen in non-human lab animals with different physiological profiles. For this reason, this drug was approved by the FDA for weight loss.
However, as with any pharmaceutical product, there is some risk of mild Semaglutide side effects. Keep in mind that the risks of Semaglutide side effects are largely limited when patients seek appropriate care and supervision from medical experts with experience administering the hormone analog.
Because Semaglutide so closely mimics the molecular structure of GLP-1, a hormone that occurs naturally, it is exceptionally well-tolerated in most patients.
The possible side effects of Semaglutide are typically mild and include:
- Abdominal pain
- Loss of appetite
To limit the risk of adverse reactions to the medication in our patients, the experts at Semaglutide For Weight Loss design protocols for patients beginning with low doses, and slowly increase them over time as necessary to achieve optimal weight loss results.
Some individuals with certain conditions should avoid Semaglutide. Please see our Contraindications section below for more information.
The FDA Officially Approves Semaglutide Specifically For Weight Loss
In 2021, on the heels of the groundbreaking research documenting the weight loss benefits of Semaglutide that we explored on our homepage, the US Food and Drug Administration (FDA) fully approved Semaglutide specifically for weight loss and weight management purposes.
Semgalutide’s approval marked the first weight loss drug awarded the green light by the FDA for weight loss in 7 years.
“Today’s approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program. FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight.”
-John Sharretts, M.D., deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research
The specific Semaglutide formulation that the FDA approved for weight loss was Wegovy, produced by Novo Nordisk.
Per pharmaceutical guidelines, individuals with certain health conditions should avoid Semaglutide. The contraindications for Semaglutide include:
- diabetic retinopathy (eye damage resulting from diabetes)
- impaired kidney function
- thyroid cancer
- family history of medullary thyroid carcinoma
- kidney disease (/w likely reduction in kidney function)
- pancreatitis (inflammation of the pancreas)
- low blood sugar
- multiple endocrine neoplasia (type 2)
Visit our semaglutide pricing page to learn about the different program lengths.